osteoporosis semaglutide GLP-1 Drugs May Raise the Risk of and Gout, Study Suggests Weight loss induced bone loss:

Your body needs a steady supply of these nutrients to maintain its "rebuilding" and "protecting" processes

The SURMOUNT-3 trial had 806 obese adults without T2D undergo 12 weeks of intensive lifestyle intervention, before randomizing the 579 participants who lost 5% of their body weight to receive either tirzepatide or a placebo

Conservative treatment is the first-line approach, but if physiotherapy fails, there is no consensus in the literature on further therapy

Both compounds are glucose-dependent in their insulinotropic activity, but retatrutide adds glucagon receptor agonism that Tirzepatide lacks

GLP-1 receptor activation suppresses appetite and slows gastric emptying